Prabalini Rajendram
YOU?
Author Swipe
View article: Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications Open
Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA approved products target various surface antigens. While CAR-T thera…
View article: Indicators of Clinical Trajectory in Patients With Cancer Who Receive Cardiopulmonary Resuscitation
Indicators of Clinical Trajectory in Patients With Cancer Who Receive Cardiopulmonary Resuscitation Open
Background: Patients with cancer who require cardiopulmonary resuscitation (CPR) historically have had low survival to hospital discharge; however, overall CPR outcomes and cancer survival have improved. Identifying patients with cancer wh…
View article: Risk factors associated with development of coinfection in critically Ill patients with COVID-19
Risk factors associated with development of coinfection in critically Ill patients with COVID-19 Open
Background: At outset of the coronavirus disease 2019 (COVID-19) pandemic, the significance of bacterial and fungal coinfections in individuals with COVID-19 was unknown. Initial reports indicated that the prevalence of coinfection in the …
View article: Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation
Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation Open
Aims In coronavirus disease 2019 (COVID-19), myocardial injury is associated with systemic inflammation and higher mortality. Our aim was to perform a proof of concept trial with canakinumab, a monoclonal antibody to interleukin-1β, in pat…
View article: Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series
Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series Open
View article: A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019
A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019 Open
Objectives: The neutrophil-lymphocyte ratio is an inexpensive and simple inflammatory marker. A higher ratio, indicative of an acute hyperinflammatory response or diminished overall physiologic health status, has been associated with poor …
View article: Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial Open
View article: Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis Open
Objectives: The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate …
View article: Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) Open
Background In patients with Covid‐19, myocardial injury and increased inflammation are associated with morbidity and mortality. We designed a proof‐of‐concept randomized controlled trial to evaluate whether treatment with canakinumab preve…
View article: Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies Open
COVID-19 is a clinical syndrome ranging from mild symptoms to severe pneumonia that often leads to respiratory failure, need for mechanical ventilation, and death. Most of the lung damage is driven by a surge in inflammatory cytokines [int…
View article: Addressing caregiver moral distress during the COVID-19 pandemic
Addressing caregiver moral distress during the COVID-19 pandemic Open
Moral distress is the psychological distress that is experienced in relation to a morally challenging situation or event. Although it was first observed within nursing, caregivers across all disciplines-including physicians, respiratory th…
View article: Ethical considerations during the COVID-19 pandemic
Ethical considerations during the COVID-19 pandemic Open
The care of patients during the COVID-19 pandemic has added many layers of complexity to ethical issues. Our response emphasizes the importance of having an ethically sound framework to inform our decisions, requiring caregivers to conside…
View article: Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2
Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2 Open
There are emerging data depicting the clinical presentation of coronavirus disease 19 (COVID-19) in solid organ transplant recipients but negligible data-driven guidance on clinical management. A biphasic course has been described in some …
View article: Practical aspects of targeting IL-6 in COVID-19 disease
Practical aspects of targeting IL-6 in COVID-19 disease Open
Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been us…
View article: The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities Open
View article: A Descriptive Report of Early Mobilization for Critically Ill Ventilated Patients With Cancer
A Descriptive Report of Early Mobilization for Critically Ill Ventilated Patients With Cancer Open
Background: Early mobilization protocols have been successfully implemented to improve function in critically ill patients; however, no study has focused on the oncology population. Objectives: To investigate the feasibility of early mobil…